Purpose {#S0001}
=======

Breast cancer is the most frequently detected cancer in women in developed countries and its incidence ranges from 25 to 30% of all cancers in women. Average age of breast cancer patients ranges between 45 and 65, in recent years there has been a noticeable trend to lower the average age of incidence \[[@CIT0001]\]. Breast conserving therapy (BCT), consisting of conservative surgery (BCS), radiotherapy (whole breast radiation therapy, WBRT) ± brachytherapy and optional adjuvant chemotherapy, is a standard radical treatment for a vast majority of breast cancer patients. Breast conserving therapy is a good alternative to mastectomy in treatment of early invasive breast cancer \[[@CIT0002]--[@CIT0005]\]. Due to further advances in radiotherapy techniques and knowledge of the biology of breast cancer, in addition to the standard methods of combination therapy (WBRT and "boost"), the application of accelerated partial breast irradiation (APBI) as a radical treatment in selected cases is increasing \[[@CIT0006]--[@CIT0009]\]. This method of radiation therapy is used in a selected group of patients in the early stages of the disease \[[@CIT0003], [@CIT0010]--[@CIT0015]\]. The main reason for the introduction of APBI was the assumption that it leads to equivalent local control rates with less toxicity of treatment compared with WBRT after BCS in the selected group of patients. The advantage of this method is also shortening the time from 5-7 weeks of treatment (WBRT + boost) to 4-5 days of APBI. It is supposed to be also able to reduce the rate of complications: radiation-induced reactions, telangiectasia and fibrosis \[[@CIT0016]\]. Treatment techniques, principles of patient selection for this method, results of treatment, and current recommendations of GEC-ESTRO (Groupe Européen de Curiethérapie -- European Society for Radiotherapy and Oncology), ABS (American Brachytherapy Society) and ASTRO (American Society for Radiation Oncology) are presented.

Rationale for the use of a boost after breast conserving surgery and whole breast radiation therapy \[[@CIT0017]\] {#S0002}
==================================================================================================================

The goal of irradiation is to minimize the risk of a local relapse within the treated breast, especially in the area of a tumor bed which is a target volume for brachytherapy. There are many methods of increasing the dose to the tumor bed (boost) \[[@CIT0017]--[@CIT0019]\]. The best approach is chosen depending on clinical and morphological criteria, patient\'s will and institutional resources and protocols. Modern interstitial multi-catheter high-dose-rate (HDR) brachytherapy offers conformal and accurate irradiation of the target volume, provided that there are surgical clips left in the operated breast and the treatment planning system is computed tomography (CT) based. Patient\'s age of \< 50 years; close, microscopically positive or unknown surgical margins; and the presence of an extensive intraductal component are accepted indications for boost irradiation \[[@CIT0020]--[@CIT0022]\]. Randomized "boost vs. no boost" trials revealed that there is an evident benefit from administering an additional dose to the tumor bed. The boost reduces 5-year local recurrence rates from 7.3-13.3% to 3.6-6.3% (*p* = 0.04-0.0001) \[[@CIT0023]--[@CIT0025]\]. Polgár *et al*. also summarized the results of many different HDR brachytherapy series worldwide, in which in total 1776 patients, a 5-year local recurrence rate of 0-9% (mean 5.5%) was achieved \[[@CIT0022]\].

Rationale for accelerated partial breast irradiation {#S0003}
====================================================

The results of studies examining the efficacy of BCS followed by WBRT showed that a very large percentage of local recurrence arises in the immediate vicinity of the original location of the tumor. At least five prospective randomized studies examining the percentage of local recurrences after radiotherapy of the whole breast were published and it was found that 69-90% of recurrences occur in the immediate vicinity of the primary tumor ([Table I](#T0001){ref-type="table"}). In other studies, the percentage of recurrences in other quadrants than in the one being treated or contralateral breast was 0.9-3.5% in prospective studies and 2-5% in retrospective studies ([Table II](#T0002){ref-type="table"}). This was the basic argument for the use of brachytherapy alone after BCS treatment in a strictly selected group of patients \[[@CIT0001], [@CIT0004], [@CIT0013], [@CIT0033], [@CIT0034]\]. Another advantage of this method pointed out by many authors is also shortening of the treatment duration of 5-7 weeks (conventional EBRT) to 4-5 days, what is important particularly for working women and living far away from the cancer center and older patients \[[@CIT0001]\]. Offeresen *et al*. \[[@CIT0035]\] in the summary pointed out that in the U.S., socio-economic factors affect the type of surgery -- poorer women (e.g. paying a lower insurance premium) and/or living far from the radiotherapy center choose mastectomy, even after qualifying for the BCS. In some areas, up to 25% of older women after BCS are not irradiated for these reasons. After examination of 175,000 patients with early breast cancer it was found that in 1992-2003, the percentage of BCS increased from 41% to 60%, while the proportion of patients irradiated after BCS decreased from 79% to 71%. Undoubtedly it affects the increased risk of local recurrences after BCS. Similar conclusions were reached by Njeh *et al*. \[[@CIT0036]\] -- in this article, they listed factors affecting radiotherapy (RT) decision: convenience, accessibility, cost, distance from the center of RT, lack of transportation, lack of social support, movement difficulties of patients, doctor bias, age of the patient, fear of radiation. Also in Japan, only about 70% of patients are treated with radiotherapy after BCS, for similar reasons as in the U.S.

###### 

Spatial pattern of ipsilateral breast relapse (IBTR) in patients enrolled in randomized trials testing the effect of the whole breast radiotherapy \[[@CIT0001]\]

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial (time of primary treatment)                            Median follow-up (range)   Recurrence number (total number of patients)   Pattern of IBTR
  ------------------------------------------------------------ -------------------------- ---------------------------------------------- -------------------------------------------------------------
  NSABP B-06 (1976-1984) \[[@CIT0010]\]                        39 (5-95) months           110 (1108)                                     86% within or close to the quadrant of the index cancer\
                                                                                                                                         14% more diffuse within the breast

  Uppsala-Orebro (1981-1988) \[[@CIT0011]\]                    10 years                   57 (381)                                       69% in the surgical field\
                                                                                                                                         3.6% in the cuticular scar\
                                                                                                                                         3.6% in the skin overlying the surgical field\
                                                                                                                                         23.6% in the breast parenchyma outside the field of surgery

  Ontario Clinical Oncology Group (1984-1989) \[[@CIT0012]\]   43 months                  131 (837)                                      86% (83% with RT) at the site of primary surgery

  Milan III (1987-1989) \[[@CIT0013]\]                         9 years                    75 (579)                                       85% (84% with RT) in the scar area\
                                                                                                                                         15% (16% with RT) in other quadrants

  SweBCG 91-RT (1991-1997) \[[@CIT0014]\]                      5 years                    104 (1178)                                     90% in the same quadrant as the previous tumour\
                                                                                                                                         10% in other quadrants
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Spatial pattern of ipsilateral breast relapse (IBTR) in patients treated with breast conserving surgery plus whole breast radiotherapy \[[@CIT0001]\]

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors, studies                                 Median follow-up (range)   Local recurrence rate (%)   Recurrence rate outside of the treated quadrant (%)   Recurrence rate in the second breast (%)
  ------------------------------------------------ -------------------------- --------------------------- ----------------------------------------------------- ------------------------------------------
  **Retrospective clinical trials (BCS + EBRT)**                                                                                                                

  Kurtz *et al*. \[[@CIT0015]\]                    11 (5-24 years)            11                          2                                                     6

  Freedman *et al*. \[[@CIT0026]\]                 5 years\                   3\                          1\                                                    3\
                                                   10 years\                  7\                          2\                                                    7\
                                                   15 years                   13                          6                                                     13

  Krauss *et al*. \[[@CIT0027]\]                   5 years\                   2\                          0.1\                                                  4\
                                                   10 years\                  7\                          2\                                                    9\
                                                   15 years                   10                          3                                                     12

  Veronesi *et al*. \[[@CIT0028]\]                 8.5 years                  6.8                         1.4                                                   5

  **Prospective trials (BCS + EBRT)**                                                                                                                           

  NSABP B-06 \[[@CIT0018]\]                        39 (5-95) months           2.7                         0.7                                                   9.4

  Uppsala-Orebro trial \[[@CIT0011]\]              10 years                   8.5                         2.1                                                   10.5

  Scottish trial \[[@CIT0029]\]                    5.7 years                  5.8                         1.4                                                   1

  Milan III \[[@CIT0028]\]                         9 years                    5.4                         1.3                                                   3.4

  NSABP B-21 \[[@CIT0030]\]                        8 years                    9.3                         2.3                                                   5.4

  SweBCG 91-RT \[[@CIT0014]\]                      61 (10-98) months          4.4                         1.1                                                   3.4

  GBCSG trial \[[@CIT0031]\]                       5.9 years                  4.2                         1                                                     2.1

  ABCSG study 8 \[[@CIT0032]\]                     53.8 months                0.5                         0.1                                                   0.5
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BCS -- breast conserving surgery, EBRT -- external beam radiation therapy

Indications for boost {#S0004}
=====================

Brachytherapy is appropriate to deliver an additional conformal boost dose to the surgical bed plus margin following standard WBRT. Ideally chosen when the physician believes that the boost dose delivery to the target is better accomplished with brachytherapy as opposed to electrons and would be dependent on the size/shape/location of the lumpectomy cavity in relation to the size/shape of the breast \[[@CIT0037]\]. While the external electron beam boost usually includes the skin and subcutaneous vessels, the interstitial implant represents a more conformal technique, which offers the advantage of lower rates of late side effects, in particular of skin telangiectasia and skin fibrosis \[[@CIT0038]--[@CIT0041]\]. Retrospective and prospective trials showed an increase in local control and an increase in survival compared to patients with no boost \[[@CIT0025], [@CIT0042]--[@CIT0044]\]. In the European Organisation for Research and Treatment of Cancer (EORTC) "boost versus no boost" randomized trial 22881/10882, 2661 patients enrolled in the boost arm were analyzed. All patients received 50 Gy WBRT and a boost dose of 16 Gy to the primary tumor bed after microscopically complete tumorectomy. Sixty-three percent of patients received a boost dose with electrons, 28% with photon beams, and 9% with interstitial brachytherapy (BT). At 5 years of follow-up, local recurrences were seen in 4.8% of patients who received an electron boost, in 4% of cases with a photon boost received, and in 2.5% of patients who underwent BT. No differences were noted in terms of late toxicities \[[@CIT0045], [@CIT0046]\].

Indications for accelerated partial breast irradiation {#S0005}
======================================================

Recommendations of the ABS and the American Society of Breast Surgeons (ASBS) regarding the qualifications for APBI are shown in [Table III](#T0003){ref-type="table"} \[[@CIT0047], [@CIT0048]\], while the GEC-ESTRO recommendations are posted in [Table IV](#T0004){ref-type="table"} \[[@CIT0049]\].

###### 

American Brachytherapy Society and American Society of Breast Surgeons selection criteria and the Eligibility Criteria for NSABP B-39/RTOG 0413 Trial \[[@CIT0048]\]

                                   ABS                                ASBS                             NSABP B-39 RTOG 0413
  -------------------------------- ---------------------------------- -------------------------------- ---------------------------------
  Age                              ≥ 50                               ≥ 45                             ≥ 18
  Histology                        Unifocal, invasive ductal cancer   Invasive ductal cancer or DCIS   Invasive adenocarcinoma or DCIS
  Tumor size                       ≤ 3 cm                             ≤ 3 cm                           ≤ 3 cm
  Surgical margins                 Negative microscopic margins       Negative microscopic margins     Negative microscopic margins
  Number of involved lymph nodes   0                                  0                                0-3

###### 

GEC-ESTRO recommendations for patient selection for accelerated partial-breast irradiation \[[@CIT0049]\]

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic             A\) Low-risk group -- good candidates for APBI         B\) Intermediate-risk group -- possible candidates for APBI   C\) High-risk group -- contraindications for APBI
  -------------------------- ------------------------------------------------------ ------------------------------------------------------------- ---------------------------------------------------
  Age                        \> 50 years                                            40-50 years                                                   \< 40 years

  Histology                  IDC, mucinous, tubular,\                               IDC, ILC, mucinous, tubular,\                                 --
                             medullary, and colloid cc.                             medullary, and colloid cc.                                    

  ILC                        Not allowed                                            Not allowed                                                   --

  Associated LCIS            Allowed                                                Allowed                                                       --

  DCIS                       Not allowed                                            Allowed                                                       --

  HG                         Any                                                    Any                                                           --

  Tumour size                pT1-2 (\< 30 mm)                                       pT1-2 (\< 30 mm)                                              pT2 (\> 30 mm), pT3, T4

  Surgical margin            Negative (\> 2 mm)                                     Negative, but close (\< 2 mm)                                 Positive

  Multicentricity            Unicentric                                             Unicentric                                                    Multicentric

  Multifocality              Unifocal                                               Multifocal (limited within 2 cm of the index lesion)          Multifocal (\> 2 cm from the index lesion)

  EIC                        Not allowed                                            Not allowed                                                   Present

  LVI                        Not allowed                                            Not allowed                                                   Present

  ER, PR Status              Any                                                    Any                                                           --

  Nodal Status               pN0 (SLNB or ALND[\*](#TF0001){ref-type="table-fn"})   pN1mi, pN1a (by ALND[\*](#TF0001){ref-type="table-fn"})       pNx;PpN2a (4 or more positive nodes)

  Neoadjuvant chemotherapy   Not allowed                                            Not allowed                                                   If used
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

APBI -- accelerated partial-breast irradiation; IDC -- invasive ductal carcinoma; ILC -- invasive lobular carcinoma; LCIS -- lobular carcinoma in situ; DCIS -- ductal carcinoma in situ; HG -- histologic grade; EIC -- extensive intraductal component; LVI -- lympho-vascular invasion; ER -- estrogen receptor; PR -- progesterone receptor; SLNB -- sentinel lymph node biopsy

ALND -- axillary lymph node dissection (at least 6 nodes pathologically examined)

Indications for brachytherapy of local recurrence {#S0006}
=================================================

Thoracic wall brachytherapy is performed with a moulded cast or standard interstitial catheters for breast cancer recurrences after mastectomy and previous irradiation to the thoracic wall. Limited recurrences can also be treated by interstitial implantation, definitively or after surgical resection \[[@CIT0003]\]. Brachytherapy represents an alternative to ultraradical surgery or external-beam reirradiation for the assurance of resection margins. Isolated local chest wall recurrence of breast cancer can be properly cured with minimal side effects by limited tumorectomy plus 20-30 Gy perioperative brachytherapy. Interstitial high-dose-rate after-loading brachytherapy is indicated for tumors with deep infiltration. For geometric optimization and the achievement of dose homogeneity, good results have been obtained by means of CT-based treatment planning \[[@CIT0050]\]. There are also a few reports about brachytherapy in the treatment of local relapses after BCS \[[@CIT0051]\].

Contraindications {#S0007}
=================

The list includes clinical stage III or IV, no evaluation of surgical margins, presence of extensive intraductal component (EIC), Paget\'s disease, infiltration or other changes in skin, present contralateral breast cancer (or in the past), previous other cancers (within 5 years from eligibility for the study) with the exception of skin cancer and 0 or Ist International Federation of Gynecology and Obstetrics (FIGO) cervical cancer (previous), pregnancy or lactation period, connective tissue disorders, collagen diseases, genetic or metabolic diseases proceeding with hypersensitivity to radiation such as Ataxia telangiectasia or similar, disorder or mental diseases, anticipated difficulties with carrying out of brachytherapy \[[@CIT0001], [@CIT0003], [@CIT0005], [@CIT0009]\]. For thoracic wall recurrences (mould technique), target areas larger than 40 cm^2^ or lesions thicker than 5 mm.

Brachytherapy techniques {#S0008}
========================

Currently, several techniques are applied: 1) interstitial brachytherapy (HDR), pulsed-dose-rate (PDR), permanent implants -- in clinical studies); 2) brachytherapy using the balloons (MammoSite, Contura); 3) hybrid brachytherapy devices (strut adjusted volume implant \[SAVI\] applicator). The latter two are performed in APBI only. Below we will discuss the basic principles of brachytherapy techniques.

Patient qualification for brachytherapy techniques \[[@CIT0001], [@CIT0052]\] {#S20009}
-----------------------------------------------------------------------------

Before preparing the treatment plan a careful evaluation of tumor size and location should be made (clinical examination, mammography, ultrasonography \[US\], sometimes magnetic resonance imaging \[MRI\]), also the stage of disease should be determined according to TNM and detailed histopathological examination should be performed. In the course of conservative treatment, it is advisable to leave 4 to 6 clips on the border of tissue removed in the axis of anterior-posterior, posterio-medial and sagittal and up and down, which will facilitate the preparation of the brachytherapy treatment plan. Clipping of the tumor bed is considered by many authors as the most precise factor determining the accuracy of brachytherapy. In the treatment planning using BT the following is also helpful: description of surgical procedures specifying the location of the scar in relation to the tumor bed, postoperative mammography, sometimes an X-ray image of the tumor bed or postoperative ultrasound.

Interstitial multicatheter brachytherapy \[[@CIT0001]\] {#S20010}
-------------------------------------------------------

Currently, two brachytherapy techniques are used in breast cancer brachytherapy: HDR and PDR:

Perioperative application of catheters {#S20011}
--------------------------------------

Brachytherapy using interstitial applicators can be performed in two ways. Perioperative brachytherapy involves the assumption of flexible applicators during surgery in place of the tumor bed. In this method, BT is applied immediately during BCS. The advantage of the perioperative technique is the need for only one general anesthesia (implantation of applicators takes place during surgery), resulting in reducing overall treatment time and the ability to precisely determine the location of the tumor visible during surgery. During a lumpectomy/quadrantectomy the surgeon provides surgical clips (should be 6) to determine the tumor bed, later they are helpful in treatment planning. Insertion of applicators requires precision, experience and basic knowledge in the field of radiation from the surgeon. The limitation of perioperative "boost" is the lack of the final histopathological examination -- the risk of incorrect BT qualification can be leveled by precise clinical staging before the procedure, intraoperative histological examination and the necessary implementation of the sentinel-lymph-node biopsy (SLNB). The irradiated area is limited to the surgical bed with a 1-1.5 cm margin depending on the technique.

Application of catheters after BCS {#S20012}
----------------------------------

Applicators are often implanted after healing of the surgical scar and after receiving the final histopathological diagnosis in 2-4 weeks after surgery. The radiation oncologist inserts applicators after visualization of the tumor bed using the X-ray (the location of surgical clips) and using ultrasound, in general or local anesthesia (depending on the experience of the center). Location of applicators on the skin with subcutaneous tissue and part of the breast is anesthetized with a solution of lidocaine or Xylocaine (2%), while analgesics are administered intravenously. General anesthesia involves standard procedures. After determining the shape and position of the tumor bed, a correct template is selected, the number of planes, the distance between the applicators and the active length for stepping source is proposed. The number of implanted applicators has to be determined individually, depending on breast size, location of the tumor bed, and type of surgery (tumorectomy, quadrantectomy). Frequently there are from 7 to over a dozen applicators. [Figure 1](#F0001){ref-type="fig"} shows images of applicators implanted in a patient with breast cancer after quadrantectomy, covering the upper external quadrant. [Figures 2](#F0002){ref-type="fig"} and [3](#F0003){ref-type="fig"} present examples of treatment plans and applicators used in interstitial BT.

![Interstitial brachytherapy for breast cancer -- implantation of 7 flexible applicators attached to the skin with buttons, the tumor bed measured by ultrasound](MR-13-22420-g001){#F0001}

![Example of 3D treatment plan for breast cancer, indicating target, applicators, and critical organs (plan prepared by Oncentra Prostate^®^)](MR-13-22420-g002){#F0002}

![The distribution of dose (isodoses) obtained after the preparation of the treatment plan, target CT cross-sections performed every 2-3 mm](MR-13-22420-g003){#F0003}

Balloon brachytherapy (MammoSite, Contura) and hybrid strut adjusted volume implant applicators \[[@CIT0001]\] {#S20013}
--------------------------------------------------------------------------------------------------------------

This technique was intended to reduce the technical difficulties associated with EBRT treatment planning and application of many interstitial applicators \[[@CIT0053], [@CIT0054]\]. The balloon applicator consists of a silicone balloon catheter containing a channel for filling the balloon and 1 to 8 channels to introduce radioisotope ([Figures 4A](#F0004){ref-type="fig"}-[B](#F0004){ref-type="fig"}). Strut adjusted volume implant applicator does not include a balloon but only applicators to adapt to the shape of the box ([Figures 5A](#F0005){ref-type="fig"}-[B](#F0005){ref-type="fig"}). Balloon technique is in principle applicable in APBI with resignation of WBRT after surgery. High-dose-rate sources are used in this technique. Balloon applicators may be placed in the bed of the tumor during the BCS (rarely) or 2-4 weeks after surgery with the help of ultrasound. Previously published results suggest a satisfactory treatment outcome (as measured by the percentage of local failure), and good cosmetic results (80% to 93% of patients) \[[@CIT0055]--[@CIT0058]\]. So far we have not had randomized studies comparing this technique treatment with interstitial BT. Maybe the response will bring the results of Phase III Trial (NSABP B-39/RTOG 0413) conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the Radiation Therapy Oncology Group (RTOG). The objective of this trial is to compare the results of different treatment methods: WBRT, APBI with MammoSite or multicatheter interstitial BT 3D EBRT in stage 0, I and II of breast cancer \[[@CIT0059]\].

![A) Contura balloon applicator (SenoRx^®^) \[[@CIT0036]\]. B) Contura balloon applicator on CT section with the distribution of isodoses, 5 channels for iridium visible](MR-13-22420-g004){#F0004}

![A) Applicator SAVI (strut adjusted volume implant) with expanded channels (Cianna Medical^®^) \[[@CIT0036]\]. B) SAVI applicator, a balloon with visible isodoses \[[@CIT0035]\]](MR-13-22420-g005){#F0005}

Balloon brachytherapy was developed as an alternative to interstitial brachytherapy. Interstitial brachytherapy requires the experience in setting up many interstitial applicators, while using balloon brachytherapy is simpler in application. Cosmetic results after balloon brachytherapy techniques seem to be very satisfactory. A high rate of satisfactory or excellent results is worth noting. To achieve such results the proper selection of patients (large breasts, the central location of the primary tumor) is important.

Technique {#S20014}
---------

The balloon applicator consists of a silicone balloon with a catheter to fill the balloon with fluid and 1 to 8 channels where a radioactive source is placed. For greater precision in most centers using this method, the balloon is fixed in the operating room under ultrasonography. Then, the applicator is fluid-filled to a volume strictly adhering to the walls of the tumor bed. Then a cross-section CT is made in order to prepare a treatment plan. Clinical target volume (CTV) includes the volume of the balloon with a margin of 1 cm. Critical organs include the skin and lungs. In this technique HDR sources are used.

Doses {#S0015}
=====

The most common dose used in a boost therapy is 10 Gy in one fraction. The most common treatment schemes of APBI techniques are: 1) fraction dose of 3.4 Gy two times daily at an interval of 6 hours, 10 fractions in 5 days to a total dose of 34 Gy; 2) fraction dose of 4 Gy two times daily -- 8 fractions to 32 Gy; 3) fraction dose of 4.3 Gy two times daily -- 7 fractions to 30.1 Gy \[[@CIT0048], [@CIT0049]\].

Conclusions {#S0016}
===========

The percentage of local recurrences and the cosmetic results are important arguments for the choice of brachytherapy technique. Brachytherapy as a boost after BCS and WBRT remains a standard technique for more than 20 years. Based on available results from prospective clinical trials where excellent results in selected groups of patients were achieved, it seems reasonable to use of APBI outside clinical trials in selected cases. This is also a conclusion of the GEC-ESTRO Breast Cancer Working Group \[[@CIT0049]\]. Strict criteria for selecting patients to the early breast cancer group (low-risk group) and systematic quality control procedures (QA) must be preserved. These recommendations may be an indication for physicians and patients to choose an APBI technique.
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